^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    irinotecan

    i
    Other names: CPT-11, CPT 11, DQ 2805, IHL-305, SN 38B11, U 101440E
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase I inhibitor
    Related drugs:
    1d
    TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens (clinicaltrials.gov)
    P2, N=21, Completed, First Affiliated Hospital, Sun Yat-Sen University | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Stivarga (regorafenib) • irinotecan
    2d
    GLIOTARG: Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas (clinicaltrials.gov)
    P=N/A, N=1000, Active, not recruiting, Blokhin's Russian Cancer Research Center
    New trial
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH wild-type
    |
    Avastin (bevacizumab) • carboplatin • irinotecan
    2d
    AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=560, Recruiting, Akeso | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Yidafan (ivonescimab)
    2d
    A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=170, Active, not recruiting, Akeso | Recruiting --> Active, not recruiting
    Enrollment closed • pMMR
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Yidafan (ivonescimab) • drebuxelimab (AK119)
    2d
    J5Q-OX-JRDA: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (clinicaltrials.gov)
    P1, N=750, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C • KRAS G12D • KRAS G12 • KRAS G12S • KRAS G13
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium
    2d
    NCI 10211: Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • MSI (Microsatellite instability)
    |
    HER-2 positive • TP53 mutation • MSI-H/dMMR
    |
    FoundationOne® CDx
    |
    irinotecan • berzosertib (M6620)
    3d
    Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort study. (PubMed, Lancet Reg Health Eur)
    Therefore, UGT1A1 genotype-guided dosing of irinotecan can be confidently performed to improve patient safety. No funding.
    Retrospective data • Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    irinotecan
    3d
    FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Oncolytics Biotech
    New P2 trial
    |
    MSI (Microsatellite instability)
    |
    RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • Reolysin (pelareorep)
    3d
    A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, Jiangsu Cancer Institute & Hospital
    New P2 trial
    |
    MSI (Microsatellite instability)
    |
    Avastin (bevacizumab) • capecitabine • oxaliplatin • irinotecan • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    4d
    Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer (clinicaltrials.gov)
    P2, N=16, Enrolling by invitation, Fudan University
    New P2 trial
    |
    5-fluorouracil • Verzenio (abemaciclib) • oxaliplatin • irinotecan • leucovorin calcium
    4d
    KEYMAKER-U06 substudy 06B: A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (clinicaltrials.gov)
    P1/2, N=230, Recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Nov 2026 --> Jun 2027
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • paclitaxel • Lenvima (lenvatinib) • irinotecan • dexamethasone • Jiataile (sacituzumab tirumotecan) • MK-4830
    7d
    Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis (clinicaltrials.gov)
    P1, N=10, Recruiting, Northwell Health | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • 5-fluorouracil • doxorubicin hydrochloride • irinotecan • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181) • AGEN2373